Tumour growth rate (TGR) to monitor growth/predict response to lanreotide autogel (LAN) use before, during and after peptide receptor radionuclide therapy (PRRT)) in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs): data from PRELUDE
Authors
Prasad, VSrirajaskanthan, R
Grana, C
Baldari, S
Shah, T
Lamarca, Angela
Courbon, F
Scheidhauer, K
Baudin, E
Thanh, X
Houchard, A
Bodei, L
Affiliation
Universit�tsklinikum Ulm, Ulm, GermanyIssue Date
2019